药源性低血压研究进展

doi:10.19803/j.1672-8629.20240733

摘要/Abstract

摘要： 目的分析药源性低血压的研究进展,为临床防范药源性低血压提供参考。方法综述国内外文献并检索Pharm-GKB数据库,系统分析增加低血压风险的药物类别及作用机制,评估药物基因多态性对低血压风险的影响,并总结现有防治策略。结果超250种药物可导致低血压,心血管药物和神经系统药物为主要风险类别。药物可通过扩张血管、抑制心脏、减少血容量等多种机制导致低血压。基因多态性显著影响药物代谢及低血压发生风险。可通过个性化用药、基于基因检测的剂量调整、避免不合理联合用药及对症治疗防治药源性低血压。结论药源性低血压应引起临床重视,未来研究可聚焦药源性低血压的预警与干预。

关键词: 药源性, 低血压, 药品不良反应, 药物基因多态性, 预防, 治疗

Abstract: Objective To investigate the research progress in drug-induced hypotension and provide clinical references for its prevention. Methods The categories drugs of associated with increased hypotension risk and their mechanisms of action were analyzed, the impact of pharmacogenetic polymorphisms on hypotension risk were evaluated, and the current prevention and treatment strategies were summarized by reviewing literature and searching PharmGKB database. Results Over 250 types of drugs were identified that could induce hypotension, with cardiovascular drugs and neurological drugs as the primary high-risk categories. Drugs could induce hypotension through such mechanisms as vasodilation, cardiac suppression, and blood volume reduction. Pharmacogenetic polymorphisms could significantly influence drug metabolism and hypotensive risk. Effective prevention strategies included personalized medications, genetic testing-guided dosage adjustment, avoidance of inappropriate drug combinations, and symptomatic treatment. Conclusion Drug-induced hypotension requires increased clinical attention. Future research should prioritize the development of predictive models and targeted intervention protocols for high-risk populations.

Key words: Drug-Induced, Hypotension, Adverse Drug Reaction, Pharmacogenetic Polymorphisms, Prevention, Treatment

中图分类号:

R972
R994.11

倪文骐, 朱峰, 周双, 崔一民. 药源性低血压研究进展[J]. 中国药物警戒, 2025, 22(4): 475-480.

NI Wenqi, ZHU Feng, ZHOU Shuang, CUI Yimin. Research Progress in Drug-Induced Hypotension[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 475-480.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240733

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I4/475

参考文献

[1] RIVASI G, RAFANELLI M, MOSSELLO E, et al.Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications[J]. Drugs Aging, 2020, 37(10): 725-738.
[2] LUO YY, LEI ZB.Research Progress of Drug-Induced Hypotension[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2010, 3(3): 121-123.
[3] KANE-GILL SL, LEBLANC JM, DASTA JF, et al.A Multicenter Study of the Point Prevalence of Drug-Induced Hypotension in the ICU[J]. Critical Care Medicine, 2014, 42(10): 2197-2203.
[4] WEI YF, WEI YZ.Observation and Nursing Interventions for Drug-Induced Hypotension[J]. Chinese Community Doctors(中国社区医师医学专业), 2011, 13(30): 274-274.
[5] WANG Y.Study on the Correlation between Frailty and Blood Pressure Variability and TCM Syndrome Elements in Elderly Patients with Hyper-tension[D]. Nanjing: Nanjing University of Chinese Medicine, 2024.
[6] HU YH, YANG XY, TANG J, et al.Recommendations for Compliance Management of Elderly Participants in Drug Clinical Trials[J]. Drug Evaluation Research(药物评价研究), 2024, 47(3): 457-462.
[7] ZHAO D, LI M, ZHENG JY, et al.A Brief Discussion on the Clinical Manifestations and Preventive Intervention Measures of Orthostatic Hypotension in the Elderly[J]. International Journal of Nursing Research(国际护理学研究), 2022, 4(4): 45-47.
[8] WIELING W, KAUFMANN H, CLAYDON VE, et al.Diagnosis and Treatment of Orthostatic Hypotension[J]. Lancet Neurol, 2022, 21(8): 735-746.
[9] LIU JJ, LI NN.Effect of Orthostatic Hypotension on Mild Cognitive Impairment in Elderly[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2021, 41(4): 315-320.
[10] ZHOU S, KONG JH, ZONG YT, et al.Advances in Research and Interventions for Drug Induced Fall Risk in the Elderly[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(1): 98-103.
[11] YANG CY, YANG C.Target Organ Damage and Research Advances in Elderly Hypertensive Patients with Orthostatic Hypotension[J]. Geriatrics & Health Care(老年医学与保健), 2023, 29(6): 1395-1398.
[12] BAHAT G, İLHAN B, TUFAN A, et al.Hypotension Under Antihypertensive Treatment and Incident Hospitalizations of Nursing Home Residents[J]. Drugs Aging, 2022, 39(6): 477-484.
[13] DANI M, DIRKSEN A, TARABORRELLI P, et al.Orthostatic Hypotension in Older People: Considerations, Diagnosis and Management[J]. Clinical Medicine (London, England), 2021, 21(3): e275-e282.
[14] GIBBON JR, FRITH J.Orthostatic Hypotension: a Pragmatic Guide to Diagnosis and Treatment[J]. Drug and Therapeutics Bulletin, 2020, 58(11): 166-171.
[15] LUO TM, LI T, NI Q, et al.Analysis of Potential Inappropriate Medication in Elderly Inpatients in our Hospital[J]. Chinese Pharma-ceutical Journal(中国药学杂志), 2022, 57(4): 315-320.
[16] LIU RL, ZHOU JN, WANG YH, et al.A Case of Hypotensive Shock Caused by Intramuscular Injection of Dezocine and Literature Review[J]. China Medicine and Pharmacy(中国医药科学), 2024, 14(2): 196-198.
[17] GUO TT, ZHU L.One Case of Empagliflozin-Induced Hypotension[J]. Central South Pharmacy(中南药学), 2022, 20(3): 715-716.
[18] MAHAJAN R, KALITA J.Tizanidine Induced Hypotension: Report of a Case and Review of the Literature[J]. Current Drug Safety, 2024, 19(2): 313-316.
[19] NKEMJIKA S, SINGH S, WAYNE K, et al.Risperidone Induced Hypotension: a Case Report and Literature Review[J]. Journal of the National Medical Association, 2022, 114(6): 621-623.
[20] PRESS Y, PUNCHIK B, FREUD T.Orthostatic Hypotension and Drug Therapy in Patients at an Outpatient Comprehensive Geriatric Assessment Unit[J]. Journal of Hypertension, 2016, 34(2): 351-358.
[21] BHANU C, NIMMONS D, PETERSEN I, et al.Drug-Induced Ortho-static Hypotension: a Systematic Review and Meta-Analysis of Randomised Controlled Trials[J]. PLoS Medicine, 2021, 18(11): e1003821.
[22] BHANU C, PETERSEN I, ORLU M, et al.Drug-Induced Orthostatic Hypotension: Cluster Analysis of Co-Prescription Patterns in Older People in UK Primary Care[J]. Pharmacoepidemiology and Drug Safety, 2024, 33(1): e5730.
[23] WANG X, MEI SS, CHEN B.Blood Pressure and Its Association with Antiparkinsonian Medications in Patients with Parkinson's Disease[J]. Chinese Journal of Neurology(中华神经科杂志), 2021, 54(12): 1312-1319.
[24] DEODHAR M, RIHANI SBA, DARAKJIAN L, et al.Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition[J]. Pharmaceutics, 2021, 13(2): 148.
[25] TANG JX, LI XX, ZHU Y.et al.Research Progress in the Relationship between Gene Polymorphisms and Drug-Induced Hypotension[J]. China Pharmacist(中国药师), 2022, 25(2): 336-340.
[26] LIU H, ZHONG H, LIN Y, et al.Association of Antihypertensive Drug-Related Gene Polymorphisms with Stroke in the Chinese Hypertensive Population[J]. International Journal of Hypertension, 2024, 2024: 5528787.
[27] HEIDARI F, VASUDEVAN R, MOHD ALI SZ, et al.Association of Insertion/Deletion Polymorphism of Angiotensin-Converting Enzyme Gene among Malay Male Hypertensive Subjects in Response to ACE Inhibitors[J]. Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16(4): 872-879.
[28] KOLOVOU V, LAGOU E, MIHAS C, et al.Angiotensinogen(AGT) M235T, AGT T174M and Angiotensin-1-Converting Enzyme(ACE) I/D Gene Polymorphisms in Essential Hypertension: Effects on Ramipril Efficacy[J]. The Open Cardiovascular Medicine Journal, 2015, 9: 118-126.
[29] BARBARINO JM, WHIRL-CARRILLO M, ALTMAN RB, et al.PharmGKB: a Worldwide Resource for Pharmacogenomic Information[J]. Wiley Interdisciplinary Reviews. Systems Biology and Medicine, 2018, 10(4): e1417.
[30] LIU Y, KONG X, JIANG Y, et al.Association of AGTR1 A1166C and CYP2C9*3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan[J]. International Journal of Hypertension, 2022, 2022: 7677252.
[31] LIN J, LIN S, WU Y, et al.Hypomethylation of the Angiotensin II Type I Receptor (AGTR1) Gene Along with Environmental Factors Increases the Risk for Essential Hypertension[J]. Cardiology, 2017, 137(2): 126-135.
[32] ORGANON. COSAAR(Losartan Potassium) Tablets[EB/OL].(2023-09-01)[2024-09-15]. https://amiko.oddb.org/de/fi?gtin=52904.
[33] YASAR U, FORSLUND-BERGENGREN C, TYBRING G, et al.Pharmacokinetics of Losartan and Its Metabolite E-3174 in Relation to the CYP2C9 Genotype[J]. Clinical Pharmacology and Therapeutics, 2002, 71(1): 89-98.
[34] PEDREROS-ROSALES C, JALIL MR, LAGOS LM, et al.Association between Cytochrome p4502c9 Polymorphisms and Losartan Dosing in Hypertensive Patients[J]. Revista Me?Dica De Chile, 2019, 147(12): 1527-1534.
[35] ZHANG YP, ZUO XC, HUANG ZJ, et al.CYP3A5 Polymorphism, Amlodipine and Hypertension[J]. Journal of Human Hypertension, 2014, 28(3): 145-149.
[36] WEN J, HUANG ZJ, YUAN H, et al.The Effect of CYP3A4*1G, CYP3A5*3 and MDR1 C3435T Gene Polymorphism on Antihypertensive Effect on Amlodipine in Hypertensive Patients after Renal Transpl-Antation[J]. Chinese Journal of Arteriosclerosis, 2011, 19(1): 55-60.
[37] YI TJ.Correlation Study between Hypertension Medication Gene and Clinical Efficacy[D]. Wuhan: Hubei University of Chinese Medicine, 2022.
[38] ZHOU J, CHEN J.Relationship of CYP3A5 Genetic Polymorphism and Efficacy of Calcium Channel Blockers in the Treatment of Chinese End-Stage Renal Disease Patients[J]. Journal of Clinical Nephrology(临床肾脏病杂志), 2016, 16(2): 81-86.
[39] FUKUDA T, ONISHI S, FUKUEN S, et al.CYP3A5 Genotype Did not Impact on Nifedipine Disposition in Healthy Volunteers[J]. Pharmacogenomics Journal, 2004, 4(1): 34-39.
[40] LIU J, LIU ZQ, YU BN, et al.Beta1-Adrenergic Receptor Polymorphisms Influence the Response to Metoprolol Monotherapy in Patients with Essential Hypertension[J]. Clinical Pharmacology and Therapeutics, 2006, 80(1): 23-32.
[41] CHEN JQ, ZHENG J, ZHU ZF, et al.Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients with Cardiovascular Diseases[J]. Frontiers in Pharmacology, 2022, 13: 876392.
[42] YANG J, WANG S, DONG TW, et al.Relationship between CYP2D6*10 Gene Polymorphism and Metoprolol Therapeutic Effect for Hypertension[J]. Chinese Journal of Cardiovascular Rehabilitation Medicine(心血管康复医学杂志), 2014, 23(2): 155-159.
[43] DUARTE JD, THOMAS CD, LEE CR, et al.Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy[Z]. Clinical Pharmacology and Therapeutics, 2024, 116(4): 939-947.
[44] WANG R, ZHAO LY, NIU XL.Research Progress in Pharmaco-genomics of Hypertension[J]. Chinese Journal of Hypertension(中华高血压杂志), 2021, 29(9): 815-819.
[45] ROBERTS RL, JOYCE PR, MULDER RT, et al.A Common P-glycoprotein Polymorphism Is Associated with Nortriptyline-Induced Postural Hypotension in Patients Treated for Major Depression[J]. Pharmacogenomics Journal, 2002, 2(3): 191-196.
[46] JENSEN BP, ROBERTS RL, VYAS R, et al.Influence of ABCB1(P-Glycoprotein) Haplotypes on Nortriptyline Pharmacokinetics and Nortriptyline-Induced Postural Hypotension in Healthy Volunteers[J]. British Journal of Clinical Pharmacology, 2012, 73(4): 619-628.
[47] REDENŠEK S, FLISAR D, KOJOVIĆ M, et al. Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease[J]. Frontiers in Pharmacology, 2019, 10: 8.
[48] TAN HS, GAN YT, TAN EC, et al.Association of Renin-Angiotensin-Aldosterone System Genetic Polymorphisms with Maternal Hypotension during Spinal Anaesthesia for Caesarean Delivery: a Retrospective Cohort Study[J]. International Journal of Obstetric Anesthesia, 2020, 44: 3-12.
[49] OLIVEIRA-PAULA GH, LACCHINI R, PINHEIRO LC, et al.Endothelial Nitric Oxide Synthase Polymorphisms Affect the Changes in Blood Pressure and Nitric Oxide Bioavailability Induced by Propofol[J]. Nitric Oxide, 2018, 75: 77-84.
[50] OLIVEIRA-PAULA GH, COELI-LACCHINI FB, FEREZIN LP, et al.Arginase II Polymorphisms Modify the Hypotensive Responses to Propofol by Affecting Nitric Oxide Bioavailability[J]. European Journal of Clinical Pharmacology, 2021, 77(6): 869-877.
[51] NIELSEN M, STAALSOE JM, ULLUM H, et al.The Gly16 Allele of the Gly16Arg Single-Nucleotide Polymorphism in the β₂-adrenergic Receptor Gene Augments Perioperative Use of Vasopressors: a Retrospective Cohort Study[J]. Anesthesia and Analgesia, 2016, 122(5): 1385-1393.
[52] LI Z, LI AY.Cytochrome Oxidase CYP1A2*C Gene Polymorphism Influencing Anesthesia Effect of Ropivacaine Hydrochlorid[J]. China Medical Engineering(中国医学工程), 2017, 25(5): 10-14.
[53] PÁL R, ANIKÓ G, PÉTER F. Drug Interactions in the Elderly, the Challenges of Combined Drug Treatment, Beers-List[J]. Lege Artis Medicinae, 2024, 34(4): 183-187.
[54] ZHAO DF, DU J, ZHAO YW, et al.Consensus of Experts on Clinical Operation of Penicillin Skin Testing[J]. Clinical Medication Journal(临床药物治疗杂志), 2022, 20(3): 10-12.
[55] Chinese Pharmacopoeia Commision.Pharmacopoeia of the People's Republic of China Clinical Guidelines for the Use of Medicines·Chemical and Biological Products 2020 Edition(中华人民共和国药典临床用药须知·化学药和生物制品 2020年版)[M]. Beijing: China Pharmaceutical Science Press, 2022.
[56] ZHAO YJ, WANG WZ, ZHANG SJ, et al.Effect of the 20° Trendelenburg Position on Hypotension during Induction of General Anesthesia of Patients Undergoing Gastrectomy[J]. Journal of Clinical Anesthesiology(临床麻醉学杂志), 2017, 33(4): 356-359.
[57] WANG YJ, CUI W.Causes and Management of Hypotension in Antihypertensive Treatment[J]. Clinical Focus(临床荟萃), 2021, 36(3): 270-276.
[58] GAO J.Study on the Antagonism Effects of Naloxone Pretreatment on the Anesthesia of Sufentanil[D]. Beijing: Beijing Institute of Technology, 2016.